Conference item icon

Conference item

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis

Subtitle:
Conference abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1002/art.39977

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Oxford college:
St Peters College
Keystone, E More by this author
Ortmann, R More by this author
Expand authors...
Publisher:
Wiley Publisher's website
Volume:
68
Issue:
S10
Pages:
Abstract: 1591
Publication date:
2016-11-08
Acceptance date:
2016-09-01
DOI:
EISSN:
2326-5205
ISSN:
2326-5191
Pubs id:
pubs:820131
URN:
uri:16fcb858-2175-4457-92f7-d2651eba5269
UUID:
uuid:16fcb858-2175-4457-92f7-d2651eba5269
Local pid:
pubs:820131

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP